Clostridium difficile Diarrhea in the Elderly: Current Issues and Management Options

被引:0
|
作者
Masako Mizusawa
Shira Doron
Sherwood Gorbach
机构
[1] Tufts Medical Center,
来源
Drugs & Aging | 2015年 / 32卷
关键词
Vancomycin; Clostridium Difficile Infection; Fecal Microbiota Transplantation; Toxic Megacolon; Fidaxomicin;
D O I
暂无
中图分类号
学科分类号
摘要
Clostridium difficile infection (CDI) is the most common cause of infectious diarrhea in healthcare settings. Along with antimicrobial exposure, advanced age has been shown to be a significant risk factor for the development and recurrence of, and mortality from, CDI. The substantial burden of CDI in the elderly may be related to frequent healthcare exposure, the necessity for more medications, altered intestinal microbiota, and complicated comorbidities. A diagnosis of CDI is based on evidence of toxin, or the C. difficile organism itself, in a stool sample in the presence of clinical signs and symptoms. Only symptomatic patients should be tested for CDI, and routine surveillance or repeat testing on asymptomatic patients as a test of cure is discouraged. Antibiotic discontinuation alone can improve or resolve CDI in some patients, and concomitant use of antibiotics is associated with decreased response to CDI treatment. Metronidazole, vancomycin, and fidaxomicin are the therapeutic agents currently available for CDI, with the selection of these agents being based on disease severity, history of recurrence, and cost. The recurrence rate after initial treatment is 20–30 %. The first recurrence can be treated with the same therapeutic agent and, for subsequent recurrences, vancomycin in a tapered and/or pulsed regimen is recommended. Fecal microbiota transplantation has shown remarkable effectiveness for recurrent anti-refractory CDI, although caution is advised in treating immunocompromised hosts and those with toxic megacolon. C. difficile can be transmitted directly and indirectly via contact with patients or their environment; therefore, isolation precautions should be initiated at the first suspicion of CDI. C. difficile spores can survive for a long time on environmental surfaces, and the patient’s room and all equipment used in the room should be disinfected. In order to manage CDI in the elderly, timely diagnosis, appropriate treatment based on severity of illness, and effective infection control are essential.
引用
收藏
页码:639 / 647
页数:8
相关论文
共 50 条
  • [21] Prevention and treatment of Clostridium difficile associated diarrhea by reconstitution of the microbiota
    Eliakim-Raz, Noa
    Bishara, Jihad
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (06) : 1453 - 1456
  • [22] Management of Primary and Recurrent Clostridium difficile Infection: An Update
    Chai, Jocelyn
    Lee, Christine H.
    ANTIBIOTICS-BASEL, 2018, 7 (03):
  • [23] Prevention of Clostridium difficile Infection and Associated Diarrhea: An Unsolved Problem
    Principi, Nicola
    Gnocchi, Margherita
    Gagliardi, Martina
    Argentiero, Alberto
    Neglia, Cosimo
    Esposito, Susanna
    MICROORGANISMS, 2020, 8 (11) : 1 - 16
  • [24] Clostridium difficile associated diarrhea: an emerging infection"
    Rampini S.K.
    Lüthi B.
    Ruef C.
    Speck R.F.
    Der Gastroenterologe, 2007, 2 (3): : 170 - 178
  • [25] Fecal Microbiota Transplantation for the Management of Clostridium difficile Infection
    Rao, Krishna
    Young, Vincent B.
    INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2015, 29 (01) : 109 - +
  • [26] Systematic Review of Current Treatment and Prevention Strategies for Clostridium difficile
    Parmar, Nicholas V.
    Glauser, Jonathan
    CURRENT EMERGENCY AND HOSPITAL MEDICINE REPORTS, 2019, 7 (03) : 66 - 73
  • [27] Cost of Clostridium difficile Associated Diarrhea in Spain
    Asensio, Angel
    Bouza, Emilio
    Grau, Santiago
    Rubio-Rodriguez, Dario
    Rubio-Terres, Carlos
    REVISTA ESPANOLA DE SALUD PUBLICA, 2013, 87 (01): : 25 - 33
  • [28] Clostridium difficile in the Long-Term Care Facility: Prevention and Management Topical Collection on Infectious Diseases in the Elderly
    Jump R.L.P.
    Donskey C.J.
    Current Geriatrics Reports, 2015, 4 (1) : 60 - 69
  • [29] Clostridioides (Clostridium) difficile infection: current and alternative therapeutic strategies
    Gil, Fernando
    Calderon, Ivan L.
    Fuentes, Juan A.
    Paredes-Sabja, Daniel
    FUTURE MICROBIOLOGY, 2018, 13 (04) : 469 - 482
  • [30] Treating Clostridium difficile infection in patients presenting with hematological malignancies: Are current guidelines applicable?
    Robin, C.
    Hequette-Ruz, R.
    Guery, B.
    Boyle, E.
    Herbaux, C.
    Galperine, T.
    MEDECINE ET MALADIES INFECTIEUSES, 2017, 47 (08): : 532 - 539